Saltar al contenido
Fuerza y músculoRevisión de revisiones3 min read

Sarcopenia linked to worse outcomes in cancer, older age and surgery, but evidence is weak

Colectivo editorial MoveVitals · Study published · Reading updated

Original paper:Sarcopenia and adverse health-related outcomes: An umbrella review of meta-analyses of observational studies. · Cancer medicine · 2020 · Artículo original ↗

Idea principal

This umbrella review of 30 meta-analyses (54 outcomes) found sarcopenia, loss of muscle mass and function, linked to worse cancer prognosis, more postoperative complications and, in older adults, more falls, fractures and all-cause mortality. Most outcomes were rated low or very low quality evidence, and observational data cannot show cause.

Study design

Revisión de revisiones

Reading basis

Published abstract

Reading focus

Design & applicability

Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.

Pregunta de investigación

Sarcopenia is increasingly discussed as a health risk, but evidence is scattered across many meta-analyses. The authors set out to map which adverse outcomes sarcopenia is associated with and how good the supporting evidence is.

Población y método

Umbrella review of meta-analyses of observational studies, comparing patients with sarcopenia with controls without it. PubMed, Web of Science and Embase were searched for systematic reviews and meta-analyses. Methodological quality was rated with AMSTAR and evidence quality with the GRADE system. 54 outcomes from 30 meta-analyses were analyzed. The abstract does not report effect sizes.

Resultados

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    20 of 21 prognostic outcomes showed sarcopenia significantly associated with poorer prognosis, across gastric, hepatocellular, urothelial, head and neck, hematological, pancreatic, breast, colorectal, lung, esophageal and ovarian cancers.
  2. 2
    10 of 16 postoperative outcomes suggested sarcopenia significantly increased multiple postoperative complications and length of hospital stay in digestive cancer patients.
  3. 3
    In older people, sarcopenia significantly increased the risk of dysphagia, cognitive impairment, fractures, falls, hospitalization and all-cause mortality. It was also associated with higher albuminuria, depression and several metabolic diseases.

Límites e incertidumbre

  1. 1
    Evidence for most outcomes was rated low or very low by GRADE, which the authors say calls for more prospective cohort studies.
  2. 2
    Included studies were observational, so low muscle mass may be a marker of frailty or illness rather than a cause of poor outcomes.
  3. 3
    The abstract gives no risk estimates, no overlap between meta-analyses and no definition of sarcopenia used across studies. This reading is based on the abstract only.

Relevancia práctica

The findings support paying attention to muscle mass and strength, especially in older age or during cancer care. They do not show that increasing muscle would prevent these outcomes, and any concern about sarcopenia should be assessed by a clinician.

Tus datos

Sarcopenia is judged by muscle mass, grip strength and walking speed, which a wearable does not measure. Steps, strength-training sessions and weight trends are useful context, and a body composition scale can show muscle trends if you compare only readings from the same device under the same conditions.

Cómo interpretar la evidencia

Reviews may reuse the same trials. Review counts are not independent replications; study quality, overlap and outcome-specific certainty matter.

Resumen estructurado de los autores English

El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.

Objective

The purpose of this umbrella review was to assess the associations between sarcopenia and adverse health-related outcomes.

Design

An umbrella review of meta-analyses of observational studies.

Setting and participants

Patients with sarcopenia and controls without sarcopenia were included.

Measures

The PubMed, Web of Science and Embase were searched for relevant systematic review and meta-analysis. AMSTAR and GRADE system were used for methodological quality and evidence quality assessments, respectively.

Results

Totally 54 outcomes extracted from 30 meta-analyses were analyzed. Twenty out of 21 prognostic outcomes indicated that sarcopenia was significantly associated with poorer prognosis of gastric cancer, hepatocellular cancer, urothelial cancer, head and neck cancer, hematological malignancy, pancreatic cancer, breast cancer, colorectal cancer, lung cancer, esophageal cancer, and ovarian cancer. Besides, 10 out of 16 postoperative outcomes suggested that sarcopenia significantly increased the risk of multiple postoperative complications and prolonged the length of hospitalization of patients with digestive cancer. In age-related outcomes, sarcopenia significantly increased the risk of dysphagia, cognitive impairment, fractures, falls, hospitalization, and all-cause mortality of elderly populations. Moreover, sarcopenia was also associated with higher level of albuminuria, risk of depression, and several metabolic diseases.

Conclusions and implications

Sarcopenia significantly affected a wide range of adverse health-related outcomes, particularly in patients of tumor and elderly populations. Because evidences of most outcomes were rated as "low" and "very low," more prospective cohort studies are required in the future.

Fuentes y atribución

Sarcopenia and adverse health-related outcomes: An umbrella review of meta-analyses of observational studies.

Xia L, Zhao R, Wan Q, Wu Y, Zhou Y, Wang Y, Cui Y, Shen X, Wu X.

Cancer medicine · 2020-09-13

DOI: 10.1002/cam4.3428 ↗PubMed · 32924316 ↗Europe PMC · Licencia registrada: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada

Fuentes verificadas 2026-11-01

Guías prácticas

Leer en contexto

·Revisión de revisiones

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Metaanálisis observacional

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
Fuerza y músculo →